Core Viewpoint - SureNano Science Ltd. has entered into a non-binding letter of intent with GlucaPharm Inc. to explore a proposed transaction for the development of a GLP-1 drug, GEP-44, which targets diabetes and weight loss with a no-needle administration method and improved tolerability [1][2] Proposed Transaction Overview - The proposed transaction is structured as a share exchange, where SureNano will acquire 100% of GlucaPharm's common shares, with GlucaPharm shareholders expected to own under 20% of SureNano's shares post-transaction [3][4] - The transaction is subject to customary due diligence, negotiation of a definitive agreement, and necessary regulatory approvals [4] GlucaPharm's Product Details - GlucaPharm holds exclusive rights to develop GEP-44, a novel GLP-1 compound that aims to improve treatment for obesity and diabetes, showing strong preclinical results and academic validation [2] Private Placement - SureNano announced a private placement to raise up to $1,250,000 by selling up to 10,000,000 units at $0.125 per unit, with each unit consisting of one common share and one warrant [6][7] - Proceeds from the private placement will be used for operating expenses, including legal fees and market exploration, and are not dependent on the acquisition of GlucaPharm [8] Company Background - SureNano Science Ltd. specializes in the sale and distribution of the SureNano™ surfactant, which enhances the performance of nanoemulsions, and holds exclusive distribution rights in Canada and certain U.S. states [9]